Results of the HEMO Study suggest that p-cresol sulfate and indoxyl sulfate are not associated with cardiovascular outcomes.

[1]  N. Powe,et al.  Trimethylamine N-Oxide and Cardiovascular Events in Hemodialysis Patients. , 2017, Journal of the American Society of Nephrology : JASN.

[2]  D. Kuypers,et al.  Microbiota-Derived Phenylacetylglutamine Associates with Overall Mortality and Cardiovascular Disease in Patients with CKD. , 2016, Journal of the American Society of Nephrology : JASN.

[3]  Connie M. Rhee,et al.  Residual Kidney Function Decline and Mortality in Incident Hemodialysis Patients. , 2016, Journal of the American Society of Nephrology : JASN.

[4]  N. Powe,et al.  Kt/Vurea and Nonurea Small Solute Levels in the Hemodialysis Study. , 2016, Journal of the American Society of Nephrology : JASN.

[5]  Jun Wang,et al.  Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota , 2015, Nature.

[6]  Alan B Leichtman,et al.  US Renal Data System 2014 Annual Data Report: Epidemiology of Kidney Disease in the United States. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[7]  N. Powe,et al.  Free Levels of Selected Organic Solutes and Cardiovascular Morbidity and Mortality in Hemodialysis Patients: Results from the Retained Organic Solutes and Clinical Outcomes (ROSCO) Investigators , 2015, PloS one.

[8]  S. Poitevin,et al.  The cardiovascular effect of the uremic solute indole-3 acetic acid. , 2015, Journal of the American Society of Nephrology : JASN.

[9]  Max Nieuwdorp,et al.  Insights Into the Role of the Microbiome in Obesity and Type 2 Diabetes , 2014, Diabetes Care.

[10]  T. Meyer,et al.  Approaches to uremia. , 2014, Journal of the American Society of Nephrology : JASN.

[11]  R. Vanholder,et al.  The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review. , 2014, Journal of the American Society of Nephrology : JASN.

[12]  T. Meyer,et al.  Prominent accumulation in hemodialysis patients of solutes normally cleared by tubular secretion. , 2014, Journal of the American Society of Nephrology : JASN.

[13]  Jens Roat Kultima,et al.  Disentangling the effects of type 2 diabetes and metformin on the human gut microbiota , 2015, Nature.

[14]  N. Powe,et al.  Retained organic solutes, patient characteristics and all-cause and cardiovascular mortality in hemodialysis: results from the retained organic solutes and clinical outcomes (ROSCO) investigators , 2013, BMC Nephrology.

[15]  Mai-Szu Wu,et al.  Serum free p-cresyl sulfate levels predict cardiovascular and all-cause mortality in elderly hemodialysis patients--a prospective cohort study. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[16]  G. Beck,et al.  Predictors of sudden cardiac death: a competing risk approach in the hemodialysis study. , 2012, American Society of Nephrology. Clinical Journal.

[17]  Bertram L Kasiske,et al.  Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). , 2011, Kidney international.

[18]  Chih-jen Wu,et al.  Serum Concentration of p-Cresol and Indoxyl Sulfate in Elderly Hemodialysis Patients , 2011 .

[19]  N. Powe,et al.  Association of residual urine output with mortality, quality of life, and inflammation in incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) Study. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[20]  K. Verbeke,et al.  p-Cresol and cardiovascular risk in mild-to-moderate kidney disease. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[21]  K. Verbeke,et al.  Free p-cresol is associated with cardiovascular disease in hemodialysis patients. , 2008, Kidney international.

[22]  T. Stijnen,et al.  Review: a gentle introduction to imputation of missing values. , 2006, Journal of clinical epidemiology.

[23]  Francesco Locatelli,et al.  Effect of dialysis dose and membrane flux in maintenance hemodialysis. , 2003, The New England journal of medicine.

[24]  M. Rocco,et al.  Comparison of causes of death using HEMO Study and HCFA end-stage renal disease death notification classification systems. The National Institutes of Health-funded Hemodialysis. Health Care Financing Administration. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[25]  A. Verstraete,et al.  Heparin-induced release of protein-bound solutes during hemodialysis is an in vitro artifact. , 2001, Clinical chemistry.

[26]  N W Levin,et al.  Design and statistical issues of the hemodialysis (HEMO) study. , 2000, Controlled clinical trials.

[27]  J. Dwyer,et al.  The hemodialysis pilot study: nutrition program and participant characteristics at baseline. The HEMO Study Group. , 1998, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.